Drug · DIN 02442183
VARIZIG
ALSO KNOWN AS VARICELLA ZOSTER IMMUNE GLOBULIN HUMAN. SINGLE-USE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since July 11, 2022; first marketed August 14, 2015.
- Drug Identification Number (DIN)
- 02442183
- Company (DIN owner)
- Ki Biopharma LlcWilmington, Delaware, United States
- Schedule
- Schedule D
- Dosage form
- Solution
- Route
- Intramuscular; Intravenous
- Therapeutic class (ATC)
- Varicella/zoster immunoglobulin J06BB03
- Class
- Human
- Record last updated
- September 17, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| VARICELLA ZOSTER IMMUNOGLOBULIN (HUMAN) | 125 UNIT | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- June 23, 2022: NOC 28457New Drug Submission (NDS) · Administrative - Change in Product Ownership
- December 19, 2017: NOC 20174New Drug Submission (NDS) · Transfer of drug identification number (din)
- May 20, 2016: NOC 18122New Drug Submission (NDS) · Transfer of din ownership
- June 18, 2015: NOC 17011Supplement to a New Drug Submission (SNDS) · New liquid formulation
Other DINs named VARIZIG
- DIN 02243342 · Cancelled Post Market